S
9.04
-0.26 (-2.80%)
| 前收盘价格 | 9.30 |
| 收盘价格 | 9.32 |
| 成交量 | 3,026,435 |
| 平均成交量 (3个月) | 2,320,008 |
| 市值 | 777,868,480 |
| 价格/销量 (P/S) | 18.83 |
| 股市价格/股市净资产 (P/B) | 9.32 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业利益率 (TTM) | -416.67% |
| 稀释每股收益 (EPS TTM) | -3.85 |
| 总债务/股东权益 (D/E MRQ) | 160.71% |
| 流动比率 (MRQ) | 5.80 |
| 营业现金流 (OCF TTM) | -286.52 M |
| 杠杆自由现金流 (LFCF TTM) | -169.65 M |
| 资产报酬率 (ROA TTM) | -36.29% |
| 股东权益报酬率 (ROE TTM) | -93.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Syndax Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.25 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.29% |
| 机构持股比例 | 120.71% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 56.00 (BTIG, 519.47%) | 购买 |
| 中 | 35.00 (287.17%) | |
| 低 | 24.00 (Goldman Sachs, 165.49%) | 购买 |
| 平均值 | 40.00 (342.48%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 13.52 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 05 Sep 2025 | 24.00 (165.49%) | 购买 | 17.04 |
| 10 Jul 2025 | 18.00 (99.12%) | 购买 | 9.82 | |
| Guggenheim | 04 Sep 2025 | 34.00 (276.11%) | 购买 | 16.19 |
| BTIG | 05 Aug 2025 | 56.00 (519.47%) | 购买 | 12.57 |
| Citigroup | 05 Aug 2025 | 51.00 (464.16%) | 购买 | 12.57 |
| UBS | 15 Jul 2025 | 35.00 (287.17%) | 购买 | 9.21 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合